T1	intervention 0 13	Anthracycline
T2	location 103 111	Kanagawa
T3	ethinicity 495 503	Japanese
T4	total-participants 643 646	103
T6	intervention-participants 704 706	53
T7	control-participants 726 728	50
T8	outcome-Measure 768 804	pathological complete response (pCR)
T10	total-participants 988 991	103
T11	total-participants 1002 1004	97
T12	intervention-participants 1033 1035	50
T13	control-participants 1051 1053	47
T14	outcome 1069 1077	pCR rate
T15	iv-bin-percent 1101 1104	36%
T16	cv-bin-percent 1121 1126	25.5%
T17	outcome 1348 1356	pCR rate
T18	outcome 1314 1342	Among patients with basal BC
T19	outcome 1435 1491	Among patients with triple-negative breast cancer (TNBC)
T20	iv-bin-percent 1394 1399	42.9%
T21	cv-bin-percent 1416 1421	13.6%
T22	outcome 1497 1500	DFS
T23	outcome 1505 1507	OS
T5	outcome-Measure 835 841	safety
T9	outcome-Measure 843 868	breast-conserving surgery
T24	outcome-Measure 870 897	disease-free survival (DFS)
T25	outcome-Measure 902 923	overall survival (OS)
T26	outcome 1194 1199	safer
T27	control 738 742	TC6.
